Adeno-associated virus vector formulations and methods
WO2020210600A1
Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
WO2020206098A1
Gene therapy for eye pathologies
TW202102526A
Recombinant adeno-associated viruses and uses thereof
WO2020102369A1
Gene therapy for neuronal ceroid lipofuscinoses
WO2020081415A1
Method for measuring the infectivity of replication defective viral vectors and viruses
AU2019319976A1
Scalable method for recombinant AAV production
TW202039857A
Treatment of mucopolysaccharidosis iva
SG11202100423YA
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idus)
WO2019241535A2
Anion exchange chromatography for recombinant aav production
WO2019212921A1
Scalable clarification process for recombinant aav production
CA3098566A1
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
WO2019079494A1
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
